Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Posts Modest Q1 Revenue Growth as Clinical, Industrial Sales Offset Completion of USPS Contract

NEW YORK, May 5 (GenomeWeb News) - Cepheid yesterday reported a 3-percent uptick in total revenues for the first quarter of 2006, accompanied by widening net losses.

 

Total revenues for the quarter ended March 31 increased 3 percent to $20.2 million from $19.6 million in the first quarter of 2005. Product sales in the clinical and industrial markets grew 89 percent year over year, but this was offset by a 19-percent drop in the biothreat market, driven by the completion of the company's contract with the United States Postal Service for installation of its GeneXpert biothreat-detection system.

 

Clinical product sales increased to $3.7 million from $1.6 million in the first quarter of 2005 and represented 19 percent of total product sales compared to 8 percent of total product sales for the first quarter of 2005.

 

Industrial product sales increased to $3.5 million from $2.2 million in the prior-year period and represented 18 percent of total product sales compared to 12 percent of total product sales last year.

 

Biothreat product sales decreased to $12.1 million from $15 million in the first quarter of 2005 and represented 63 percent of total product sales compared to 80 percent in the year-ago period.

 

Cepheid's first-quarter net loss widened to $6.7 million, or $.15 per share, from $3.5 million, or $.08 per share, for the prior-year period. The company said that the net loss for 2006 includes $1.7 million of stock compensation expense.

 

R&D spending increased to $5.8 million from $4.5 million in the first quarter of 2005.

 

As of March 31, the company had $59.7 million in cash and cash equivalents, and $108.8 million in unrestricted cash and marketable securities.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.